Team
Management Team
Albert Gianchetti
Chief Executive Officer
Over 30 years of experience in drug development and commercialization, including more than a decade in cardiovascular and metabolic therapeutic areas. Has held senior executive roles across pharma and biotech companies, driving strategy, operations and R&D, with proven ability to raise capital and to lead biotech companies through clinical development. Has directed multiple Phase III and Phase I/II clinical programs and delivered several successful product launches.
Jitindera Bhatia, PhD
Senior Vice President, CMC
Experienced scientist and quality leader with over 25 years in pharmaceutical CMC including USP, DSP and formulation development. Over 10 years of experience in AAV gene therapy, formerly as SVP CMC at Corlieve Therapeutics, acquired by uniQure NV and CMC Project Lead at Freeline Therapeutics. Brings expertise in GMP, tech transfer and QMS implementation.
Christian Beck, PhD
Vice President, Corporate Development
Scientist by training with 10 years of experience across M&A, corporate finance & strategy, and business development in the biopharma sector, including executing multiple transformational transactions at leading global investment banks such as Lazard and Citi.
Nicolas Guyon-Gellin, MD
Chief Business Officer
Over 18 years of experience in Biotech industry and global healthcare financial markets. Began career as an emergency care doctor before transitioning into the finance sector, spending a decade as a Healthcare Equity Research Analyst at leading firms and banks (Morgan Stanley London, Amundi and Exane BNP Paris). In 2017, moved into biotech as a BD & Strategy executive, first with Enyo Pharma in Lyon, then as CBO at Calypso Biotech in Geneva, which was acquired by Novartis in 2024.
Lucie Rouch
Vice President, Clinical Operations
Seasoned clinical operations leader with more than 20 years of experience in pharmaceutical development, specializing in innovative therapies and rare diseases, with a proven track record and demonstrated capability of successfully delivering clinical programs. Has held multiple clinical operation roles at Ipsen, Sanofi, Lysogene, Enterome and global CROs including PPD and ICON.
Cheryl Lee
Vice President, Operations
Business operator with over 15 years of experience driving growth, optimizing resources and supporting strategic initiatives within complex, high-growth life sciences organizations.
Board of Directors
Andreas Wallnoefer, PhD, MBA
Board Chairman
Over 25 years of experience in the biopharma industry including 12 years as a member of the F. Hoffmann-La Roche Pharma R&D Executive Leadership team. Involved in the development of several important medicines that reached the market at Roche and contributed to the build-up of several companies and successful M&A exits.
Mia Hu, PhD
Board Member
Boehringer Ingelheim Venture Fund
Thierry Abribat, PhD
Board Member
Accomplished biotech entrepreneur with a remarkable track record of founding and successfully exiting three biotech companies. Most recently, led Amolyt Pharma from founding to its >$1bn acquisition by AstraZeneca.
Khoo Shih, PhD
Board Member
ClavystBio
Elia Stupka, PhD
Board Member
Angelini Ventures
Amanda Gett-Chaperot,
PhD, MBA
Board Member
Kurma Partners
Advisors
Brian Burke, PhD
Co-Founder and Advisor
Former Research Director at the Agency for Science, Technology and Research, Singapore. Distinguished cell biologist in the area of the nuclear envelope, including lamins and the LINC complex through the innovative use of microscopic and biochemical technologies.
Mark Kay, MD, PhD
Co-Founder and Advisor
Head of the Division of Human Gene Therapy; and Professor of Pediatrics and Genetics at Stanford University.
World expert in the area of gene therapy technologies for the treatment of genetic and acquired diseases, including the discovery of novel adeno-associated virus (AAV) capsids.
Colin Stewart, PhD
Co-Founder and Advisor
Former Research Director at the Agency for Science, Technology and Research, Singapore. Pioneer in techniques underpinning mouse experimental genetics, and developer of multiple mouse models for laminopathies for elucidating mechanisms of disease.